To circumvent liver toxicity, targeting strategies to restrict CD137 exposure and crosslinking to the tumor microenvironment are already under clinical development as single agents or in combination with PD-L1 checkpoints inhibitors5,19,20. This evidence concerns the gene TNFRSF9 and neoplasm.